News
ACR Weighs in on APP Loans and Professional Degrees
ACR
The American College of Rheumatology (ACR) recently joined with 16 other healthcare organizations to submit comments to the U.S.
NEJM: Obinutuzumab in Active Systemic Lupus Erythematosus
A phase 3 trial of obinutuzumab, an anti-CD20 monoclonal antibody, showed potent B-cell depletion and clinical efficacy active systemic lupus erythematosus without evidence of nephritis.
Long-Term Hydroxychloroquine Retinopathy Risk
About one in 18 patients taking hydroxychloroquine (HCQ) for 15 years develop retinal damage, a new meta-analysis indicated.
TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis
On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active psoriatic arthritis (PsA) based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials.
UBER Rheumatology Ride (3.6.2026)
Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com
The Role of Calcineurin Inhibitors in Lupus Nephritis
In the U.S, lupus nephritis affects approximately 40–50% of patients with systemic lupus erythematosus, contributing significantly to the morbidity and mortality of the affected individuals. However, significant differences in clinical approaches to lupus nephritis management still persist.
Osteoporosis: Thinking outside the box
As rheumatologists, most of us manage osteoporosis in some form every single day. We have newer agents, newer sequencing strategies, and an increasing number of patients asking for “less medicinal” options that go beyond a prescription. At RWCS, Dr. Gina Woods opened her talk by reframing osteoporosis as a comprehensive approach to bone and muscle health rather than a narrow discussion about a DEXA report.
Open-access Arthralgia Clinics
The early diagnosis in inflammatory arthritis (IA), particularly rheumatoid arthritis (RA), hinges on efficient referral and screening of arthralgia patients.
Treat-to-Target and Cardiovascular Benefits in Gout
A new user cohort study of 109 504 gout patients, achieving a serum urate level less than 6 mg/dL, was associated with a significantly lower risk of cardiovascular events.
B cell Targeted CAR-T Therapy for Autoimmune Diseases
EurekAlert!
Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with unprecedented specificity.
Hydroxychloroquine Lowers SLE and RA Hospitalizations
A population based study from British Columbia, Canada, shows that antimalarial adherence was associated with a lower risk of hospital admission in patients with rheumatoid arthritis
